Haleon is preparing to offer part of its shares on the New York Stock Exchange next Wednesday, after it offered a share of the company on the London Stock Exchange on Monday.
This follows the announcement of its separation from parent company GlaxoSythmicline to become an independent company.
Haleon has a portfolio of brands including Panadol, Sensodyne, Otrivin and Voltaren, and will continue to develop category leading brands that address real consumer health needs, while focusing on future innovation across its entire portfolio.
With an increased consumer focus on health and wellness, an ageing global population, an emerging middle class in high-growth economies, growing self-care in the face of increased pressure on public healthcare systems and sizeable unmet consumer needs, Haleon has launched at a time when the consumer healthcare market is set for expansion (expected to be at a rate of 3-4% per annum over the medium-term). Haleon expects to deliver medium-term annual organic revenue growth of 4-6%.
Despite huge improvements in medicine, data and technology, everyday health remains elusive for too many people. Haleon aims to change this through a two-pronged approach. First, by working to remove barriers to better everyday health, and second, by aiming to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health.
Brian McNamara, CEO of Haleon, said: “This is a significant milestone for Haleon. Guided by our clear purpose and with a world class portfolio of brands that people know and trust, we stand ready to help address consumer needs and make better everyday health more achievable, inclusive and sustainable.
Consumer health has never been more important than it is today, and I am delighted that Haleon, as an independent company, is now ready to pursue our ambitions. Today follows a huge amount of effort, planning and collaboration by our dedicated colleagues all around the world.”
Nabil Besri, General Manager of Haleon in North Africa, said: “Today is a big milestone for our company as we are becoming the world’s first standalone consumer healthcare company. This transformation will help us to accelerate our efforts in Egypt and throughout North Africa to drive our self-care agenda to enable better access for better everyday health. We will work closely with our business partners to bring brands people love and trust and continue to make a meaningful impact on millions of our consumers’ lives by combining trusted science and deep human understanding.”
